To include your compound in the COVID-19 Resource Center, submit it here.

Paion, Cosmo deal

Paion granted Cosmo’s Cosmo Technologies Ltd. subsidiary exclusive U.S. rights to develop and commercialize remimazolam, an ultra-short-acting

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE